Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens chromatin licensing and DNA replication factor 1 (CDT1)
Synonyms:
DUP; RIS2
Immunogen
A synthetic peptide corresponding to residues near the C-terminus of human CDT1 was used as an immunogen.
Buffer
Store at -20 C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
CDT1 is a novel replication factor conserved throughout evolution, and it was first identified in S. pombe as a target of CDC10 transcriptional regulation. It has been demonstrated that CDT1 cooperates with CDC18/CDC6 in driving re-replication in G2 when the CDC18/CDC6 protein is overexpressed and that CDT1 depletion prevents the binding of MCM proteins to chromatin (1). Regulation of CDT1 plays a critical role in the licensing process. Inhibition of CDT1 activity occurs by multiple mechanisms, including ubiquitin-dependent proteolysis and binding to its potent inhibitor Geminin. Misregulation of the licensing process and defects in the ordered assembly and disassembly of the pre-RC alter the integrity of the genome. Thus, cell cycle regulation of CDT1 expression and function is responsible for licensing replication origins in G1 and preventing relicensing and hence rereplication in S phase.
Related Pathway
Cell cycle
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
